Sheet 1 of 1

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00216-654001	Application No. 10/721,118
	Applicant Cheng Hwang et al.		
	Filing Date November 25, 2003	Group Art Unit 1615 / 1617	


U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
G4 ↓	AA	US 2004/0052760 A1	03/18/04	Michelet et al.			
	AB	6,093,748	07/25/00	Ahluwalia et al.			
	AC	6,004,751	12/21/99	Rosenfeld			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AQ	
	AR	
	AS	
	AT	

Examiner Signature <i>Gina Yu</i>	Date Considered <i>10/11/07</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

Sheet 1 of 5

Substitute Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
00216-654001Application No.  
10/721,118**Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant  
Cheng Hwang et al.Filing Date  
November 25, 2003Group Art Unit  
1615/617**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
QY	AA	2002/0052416 A1	05/02/02	Michelet et al.			
	AB	2002/0052414 A1	05/02/02	Bernard et al.			
	AC	2002/0045659 A1	04/18/02	Michelet et al.			
	AD	2002/0044953 A1	04/18/02	Michelet et al.			
	AE	6,369,098	04/09/02	Pershad Singh et al.			
	AF	2002/0019338 A1	02/14/02	Hebert			
	AG	6,299,865 B1	10/09/01	Styczynski et al.			
	AH	6,284,234	09/07/01	Niemiec et al.			
	AI	6,248,751 B1	06/19/01	Ahluwalia et al.			
	AJ	6,239,170 B1	05/29/01	Ahluwalia et al.			
	AK	6,235,737 B1	05/22/01	Styczynski et al.			
	AL	6,218,435 B1	04/17/01	Henry et al.			
	AM	6,121,269	09/19/00	Henry et al.			
	AN	6,093,748	07/25/00	Ahluwalia et al.			
	AO	6,060,471	05/09/00	Styczynski et al.			
	AP	6,037,326	03/14/00	Styczynski et al.			
	AQ	6,020,006	02/01/00	Styczynski et al.			
	AR	5,972,944	10/26/99	Antonucci et al.			
	AS	5,962,466	10/05/99	Styczynski et al.			
	AT	5,958,946	09/28/99	Styczynski et al.			
	AU	5,939,458	08/17/99	Henry et al.			
	AV	5,908,867	06/01/99	Henry et al.			
	AW	5,866,595	02/02/99	Pershad Singh et al.			
	AX	5,840,752	11/24/98	Henry et al.			
	AY	5,824,694	10/20/98	Kurtz et al.			
	AZ	5,824,665	10/20/98	Henry et al.			
✓	AAA	5,776,442	07/07/98	Ahluwalia			

Examiner Signature

Gina Yu

Date Considered

10 / 11 / 07

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00216-654001	Application No. 10/721,118
	Applicant Cheng Hwang et al.		
	Filing Date November 25, 2003	Group Art Unit 1615 1017	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
GY	BA	5,728,736	03/07/98	Shander et al.			
	BB	5,700,835	12/23/97	Dean et al.			
	BC	5,674,477	10/07/97	Ahluwalia			
	BD	5,652,273	07/29/97	Henry et al.			
	BE	5,648,394	07/15/97	Boxall et al.			
	BF	5,645,825	07/08/97	Hillebrand et al.			
	BG	5,554,608	09/10/96	Ahluwalia et al.			
	BH	5,474,763	12/12/95	Shander et al.			
	BI	5,468,476	11/31/95	Ahluwalia et al.			
	BJ	5,455,234	10/03/95	Ahluwalia et al.			
	BK	5,444,090	08/22/95	Ahluwalia			
	BL	5,411,991	05/02/95	Shander et al.			
	BM	5,364,885	11/15/94	Ahluwalia et al.			
	BN	5,362,748	11/08/94	Schwen et al.			
	BO	5,328,686	07/12/94	Shander et al.			
	BP	5,300,284	04/05/94	Wiechers et al.			
	BQ	5,271,942	12/21/93	Heverhagen			
	BR	5,189,212	02/23/93	Ruenitz			
	BS	5,143,925	09/01/92	Shander et al.			
	BT	5,132,293	07/21/92	Shander et al.			
	BU	5,096,911	03/17/92	Ahluwalia et al.			
	BV	5,095,007	03/10/92	Ahluwalia			
	BW	4,935,231	06/19/90	Pigiet			
	BX	4,885,289	12/05/89	Breuer et al.			
	BY	4,720,489	01/19/88	Shander			
	BZ	4,562,204	12/31/85	Wakatsuka et al.			
	BAA	4,517,175	05/14/85	Iwabuchi et al.			

Examiner Signature <i>Gina Yu</i>	Date Considered <i>10 / 11 / 07</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00216-654001	Application No. 10/721,118
		Applicant Cheng Hwang et al.	
		Filing Date November 25, 2003	Group Art Unit 1615

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
G4	CA	4,508,714	04/02/85	Cecic et al.			
	CB	4,370,315	01/25/83	Greff et al.			
	CC	4,269,831	05/26/81	Ferrari et al.			
	CD	4,203,924	05/20/80	Nelson			
	CE	4,201,873	05/06/80	Peterson			
	CF	4,191,775	03/04/80	Glen			
	CG	4,161,540	07/17/79	Neri et al.			
	CH	4,139,638	02/13/79	Neri et al.			
	CI	4,039,669	08/02/77	Beyler et al.			
	CJ	3,426,137	02/04/69	Philpitt et al.			
	CK	3,878,239	04/15/75	Hyashi et al.			
	CL	3,426,137	02/04/69	Philipitt et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
G4	CM	WO 03/020209 A2	03/13/03	PCT				
	CN	WO 02/13812 A1	02/21/02	PCT				
	CO	WO 01/74315 A2	10/11/01	PCT				
	CP	WO 01/74314 A2	10/11/01	PCT				
	CQ	WO 01/74313 A2	10/11/01	PCT				
	CR	WO 01/74307 A2	10/11/01	PCT				
	CS	WO 01/62237 A3	08/30/01	PCT				
	CT	WO 01/54654 A2	08/02/01	PCT				
	CU	WO 00/62766	10/26/00	PCT				
	CV	WO 00/50002	08/31/00	PCT				
	CW	WO 00/48559	08/24/00	PCT				
	CX	WO 98/02134	01/22/98	PCT				

Examiner Signature <i>Gina Yh</i>	Date Considered 10 / 11 / 07
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00216-654001	Application No. 10/721,118
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Cheng Hwang et al.	
		Filing Date November 25, 2003	Group Art Unit 1615

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
GY	DA	EP 0 413 528	11/15/95	EPO				
	DB	WO 94/21216	09/29/94	PCT				
	DC	0 532 219 A2	09/02/92	EPO				
	DD	WO 92/10164	06/25/92	PCT				
	DE	EP 0 098 141	06/29/84	EPO				
	DF	EP 0 097 023	12/28/83	EPO				
	DG	1 458 349	1215/76	London				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
GY	DH	Malholtra et al., "Percutaneous Absorption and Pharmacokinetics of Eflornithine HCl 13.9% Cream in Women with Unwanted Facial Hair", Journal of Clinical Pharmacology, Vol. 41, No. 9, pp. 972-978, September 2001
	DI	Beisson et al., "Use of the Tape Stripping Technique for Directly Quantifying Esterase Activities in Human Stratum Corneum", Analytical Biochemistry, Vol. 290, No. 2, pp. 179-185, March 15, 2001
	DJ	Moretti et al., "Oncostatic Activity of a Thiazolidinedione Derivative on Human Androgen-Dependent Prostate Cancer Cells", Int. J. Cancer: 92, 733-737 (2001)
	DK	Breyer et al., "Prostanoid Receptors: Subtypes and Signaling", Annu. Rev. Pharmacol. Toxicol., 41:661-90, 2001
	DL	Ellis, et al., "Troglitazone Improves Psoriasis and Normalizes Models of Proliferative Skin Disease", Arch. Dermatol, 136, p. 609-616, May 2000
	DM	Corton et al., "Central Role of Peroxisome Proliferator-Activated Receptors in the Actions of Peroxisome Proliferators, Annu. Rev. Pharmacol. Toxicol., 40:491-518, 2000
	DN	Kersten et al., "Peroxisome Proliferator Activated Receptor Agonists", New Approaches to Drug Development, pp. 141-151, 2000
	DO	Balfour et al., "Rosiglitazone", Drugs, 57 (6) pp. 922-930, June 2000
	DP	Lawrence et al., "Pioglitazone", IJCP, Vol. 54, No. 9, pp. 614-618. November 2000
	DQ	Wright et al., "The human protanoid DP receptor stimulates mucin secretion in LS174T cells", British Journal of Pharmacology, 131, 1537-1545, (2000)
	DR	Narumiya et al., "Prostanoid Receptors: Structures, Properties, and Functions", Physiological Reviews, Vol. 79, No. 4, 1193-1226, October 1999
	DS	Breider et al., "Troglitazone-Induced Heart and Adipose Tissue Cell Proliferation in Mice, Toxicology Pathology, Vol. 27, No. 5, pp. 545-552, 1999
	DT	Crider et al., "Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: pharmacological characterization using agonists and antagonists", British Journal of Pharmacology, 127, 204-210 (1999)

Examiner Signature <i>Gina Yu</i>	Date Considered 10/ 11 /07
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 00216-654001	Application No. 10/721,118
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Cheng Hwang et al.	
		Filing Date November 25, 2003	Group Art Unit 1615
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
Gy	EA	Botchkarev et al., "A New Role for Neurotrophin-3", <i>American Journal of Pathology</i> , Volume 153, pp. 785-799, 1998.
	EB	Botchkarev et al., "Neurotrophin-3 Involvement in the Regulation of Hair Follicle Morphogenesis", <i>The Journal of Investigative Dermatology</i> , Volume 111, No. 2, pp. 279-285, 1998.
	EC	Wright et al., "Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist", <i>British Journal of Pharmacology</i> , 123, 1317-1324 (1998)
	ED	Robert R. Henry, "Thiazolidinediones", <i>Current Therapies for Diabetics</i> , Vol. 26, No. 3, pp.553-573, September 1997
	EE	Hoffmann et al., "Interleukin-1 $\beta$ -Induced Inhibition of Hair Growth <i>In Vitro</i> Is Mediated by Cyclic AMP", <i>The Journal of Investigative Dermatology</i> , Volume 108, pp. 40-42, 1997.
	EF	Messenger, Andrew G., "The Control of Hair Growth: An Overview", <i>The Journal of Investigative Dermatology</i> , Volume 101, No. 1, pp. 4s-9s, 1993.
	EG	Weinberg et al., "Reconstitution of Hair Follicle Development <i>In Vitro</i> : Determination of Follicle Formation, Hair Growth, and Hair Quality by Dermal Cells", <i>The Journal of Investigative Dermatology</i> , Volume 100, pp. 229-236, 1993.
	EH	Alvarez et al., "Stimulation of Prostaglandin D <sub>2</sub> Receptors on Human Platelets by Analogs of Prostacyclin", <i>Prostaglandins</i> , Vol. 42, No. 2, pp. 105-119, August 1991
	EI	Geissler et al., "Thiazolidine-Diones Biochemical and Biological Activity of a Novel Class of Tyrosine Protein Kinase Inhibitors", <i>The Journal of Biological Chemistry</i> , Vol. 265, No. 36, pp. 22255-22261 December 25, 1990
	EJ	Heinz-Thierauch et al., "ZK 110 841 - A Selective and Potent Prostaglandin D <sub>2</sub> Analogue", <i>Prostaglandins in Clinical Research: Cardiovascular System</i> , pp. 597-601, 1989
	EK	Hirata et al., "Occurrence of 9-Deoxy- $\Delta^9$ , $\Delta^{12}$ -13,14-dihydroprostaglandin D <sub>2</sub> in Human Urine, <i>The Journal of Biological Chemistry</i> , Vol. 263, No. 32, pp. 16619-16625, November 15, 1988
	EL	Heinz-Thierauch et al., "Stable 9 $\beta$ - or 11 $\alpha$ -Halogen-15-Cyclomethyl -Prostaglandins with High Affinity to the PGD <sub>2</sub> -Receptor", <i>Prostaglandins</i> , Vol. 35, No. 6, pp. 855-868, June 1988
	EM	Ebling, F. John G., "The Biology of Hair", <i>Dermatologic Clinics</i> , Volume 5, No. 3, pp. 467-481, 1987.
	EN	Hattori et al., "Biochemical Analysis of Hair Growth From the Aspects of Aging and Enzyme Activities", <i>The Journal of Dermatology</i> , Volume 10, pp. 45-54, 1983.
	EO	Bundy et al., "Synthesis and Platelet Aggregation Inhibiting Activity of Prostaglandin D Analogues", <i>J. Med. Chem.</i> , 26, pp. 790-799, 1983
	EP	Town et al., "Pharmacological and Cardiovascular Properties of a Hydantoin Derivative, BW 245 C, with High Affinity and Selectivity for PGD <sub>2</sub> Receptors", <i>Prostaglandins</i> , Vol. 25, No. 1, pp. 13-28, January 1983
	EQ	Caldwell et al., "Heterocyclic Prostaglandin Analogues. Part 2. <sup>1</sup> Hydantoins and Other Imidazole Analogues", <i>J. Chemical Society</i> , Vol. 1, pp. 495-505, 1980
	ER	Sato, Yoshio, "The Hair Cycle and Its Control Mechanism", pp. 3-13, 1976
✓	ES	Adachi et al., "Human Hair Follicles: Metabolism and Control Mechanisms", <i>Journal of the Society of Cosmetic Chemists</i> , Volume 21, Number 13, pp. 901-924, 1970.

Examiner Signature Gina YW	Date Considered 10 / 11 / 07
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	